ALGAIA

Their core work

Algaia is a French company specializing in algae-based biorefinery, producing high-value compounds from both macroalgae and microalgae (notably spirulina). They develop extraction processes for bioactive ingredients like phycocyanin and marine enzymes, targeting food, functional food, and health applications. Their work spans the full chain from large-scale algae cultivation through biomass processing to market-ready ingredient production.

What they specialise in

How they've shifted over time

Algaia's early H2020 work (2017–2018) centered on marine seaweed — large-scale aquaculture, IMTA systems, and marine enzyme extraction through GENIALG. From 2018 onward, focus shifted toward microalgae, specifically spirulina-based phycocyanin production (SpiralG), and then into health-oriented functional foods targeting inflammatory bowel disease (Algae4IBD). The trajectory shows a clear move from upstream marine biomass production toward downstream high-value health ingredients.

Algaia is moving from bulk algae processing toward targeted bioactive compounds for human health, particularly gut health and inflammation — expect future projects at the food-pharma intersection.

How they like to work

Algaia operates primarily as a partner rather than a leader, having coordinated just one of three projects (SpiralG). With 45 unique consortium partners across 13 countries, they work in broad European consortia rather than small focused teams. Their coordinator role in SpiralG — an Innovation Action — suggests they are comfortable leading when the project is close to market application and their core spirulina expertise.

Algaia has built a network of 45 partners across 13 countries through just 3 projects, indicating participation in large, well-connected consortia. Their reach spans Western Europe with strong ties to marine and food research clusters.

What sets them apart

Algaia bridges the gap between algae cultivation and commercial ingredient production — they are not a research lab studying algae, but an industrial partner who knows how to extract, process, and bring algae-derived compounds to market. Their location in Lannilis (Brittany, France) places them in one of Europe's premier seaweed regions, giving them access to both raw material supply chains and marine biotech expertise. Few private companies combine hands-on biorefinery capability with experience in both macro- and microalgae value chains.

Highlights from their portfolio

• GENIALG
  Large-scale macroalgal biorefinery project that established Algaia's credentials in seaweed aquaculture and marine enzyme extraction across European supply chains.
• SpiralG
  Algaia's only coordinator role — an Innovation Action focused on commercializing phycocyanin extraction from spirulina, their largest single EU funding (EUR 617,693).
• Algae4IBD
  Represents Algaia's push into health applications, targeting inflammatory bowel disease with algae-based functional foods — a significant pivot from pure biomass processing.